2022 has been a very active year for Targovax and our sector, and we invite you
to an Investor Event Tuesday 27 September 2022. DNB will provide an analyst's
view of the biotech industry followed by presentations from Targovax with a
focus on circRNA. We will finish the event with an opportunity for you to speak
with members of our management team in an informal setting with food and
refreshments.

Targovax's management team will present in Norwegian and are available for
questions during the social event.

Date: Tuesday 27 September
Time: 17.00-19.00
Location: Sentralen, Øvre Slottsgate 3, Oslo

  · An analyst's view of the biotech market
    · Dr. Geir Hiller Holom, Senior Equity Analyst at DNB Markets

  · Targovax Business Overview
    · Dr. Erik Digman Wiklund, CEO of Targovax

  · Circular RNA (circRNA) - the new frontier in RNA therapeutics discovered in
Scandinavia
    · Dr. Thomas Hansen, VP Research at Targovax

There will be an informal Q&A and serving of food from 17:45.

Lubor Gaal, CFO og Andreas Storsve, VP Business Development, will also be
present.

Registration by Monday 26 September at 12:00 to
renate.birkeli@targovax.com (renate.birkeli@targovax.com?subject=Attendance%20at
%
20Investor%20Event%2027%20September&body=Hi%2C%20%0A%0AI%20would%20like%20to%20r
e
gister%20for%20the%20investor%20event%2027th%20September.%20)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and multiple myeloma, and has demonstrated a favorable
safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system against the tumor. Following very
encouraging clinical data in several indications, both as monotherapy and in
combinations, ONCOS-102 is progressing into a randomized phase 2 trial in
melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Building on successful studies demonstrating clinical efficacy and providing
deep mechanistic insights, the Targovax platform is being expanded into delivery
of circular RNA (circRNA). In addition, Targovax has a KRAS immunotherapy
program, with lead cancer vaccine candidate, TG01, due to enter the clinic in
the second half of 2022. This provides Targovax with a rich pipeline of
innovative future immunotherapy product candidates to follow ONCOS-102.